Pair page
Eloralintide with Semaglutide
Mechanism-tag overlap and published literature for Eloralintide and Semaglutide, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
selective-amylin-receptor-agonist
glp-1-receptor-agonistmetabolic
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Eloralintide and Semaglutide have published these mechanism-level observations. Not a co-administration recommendation.
Mechanistically similar to the CagriSema logic (GLP-1 + amylin). Not part of Lilly's declared combination program with eloralintide but biologically plausible. Lilly will commercially pursue tirzepatide-combo rather than cross-company semaglutide pairing.
Quick facts
Eloralintide
Semaglutide
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2025 | Eloralintide | Eli Lilly and Company. Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight. Press release, November 6, 2025. (Phase 2 topline announcement; Phase 3 enrollment initi… | human trial, Phase 3 |
| 2025 | Eloralintide | Billings LK, Hansen HH, Dam-Larsen S, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2025. PMID: 41207310. (NCT06230523 — pivotal Phase 2; up to 20… PMID 41207310 | human trial, Phase 2 |
| 2023 | Eloralintide | Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023;402(10403):720-730.… PMID 37515693 | human trial, Phase 2 |
| 2021 | Eloralintide | Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160-2172. PMID:… PMID 34798049 | human trial, Phase 2 |
| — | Eloralintide | ClinicalTrials.gov NCT06230523 — A Study of LY3841136 in Adult Participants With Obesity or Overweight. (Pivotal Phase 2.) | human trial, Phase 2 |
| — | Eloralintide | ClinicalTrials.gov NCT06603571 — A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes. (Combination Phase 2.) | human trial, Phase 2 |
| — | Eloralintide | ClinicalTrials.gov NCT06297616, NCT06916091 — Additional Phase 2 eloralintide monotherapy programs. | human trial, Phase 2 |
| 2025 | Eloralintide | Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. 2025. PMID: 41559929. (Phase 1 multiple-ascending-dose results; 100 participants, up to ~11% weight loss at 12 weeks.) PMID 41559929 | human trial, Phase 1 |
| — | Eloralintide | ClinicalTrials.gov NCT05295940 — A Study of LY3841136 in Healthy Participants. (Phase 1 SAD/MAD.) | human trial, Phase 1 |
| 2025 | Eloralintide | Briere DA, Bueno AB, Gimeno RE, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Mol Metab. 2025. PMID: 41109426. (Full translational characterization; AMY1R selectivity, preclinical weigh… PMID 41109426 | preclinical, in vivo |
| 2025 | Eloralintide | Briere DA, Long A, Bullock DM, et al. 849-P: Eloralintide (LY3841136), a Selective Amylin Mimetic, Lowered Body Weight with Improved Quality of Weight Loss and GI Tolerability in Rats Compared with Cagrilintide. Diabetes 2025;74(Suppl 1):849-P. (ADA 2025 scientific sessions prec… | preclinical, in vivo |
| 2025 | Eloralintide | Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus. Nat Rev Endocrinol. 2025;21:482-494. (Modern review of the amylin drug class including eloralintide context.) | review |
| 2024 | Semaglutide | Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). N Engl J Med. 2024;391(2):109-121. PMID: 38785209. PMID 38785209 | human trial |
| 2023 | Semaglutide | Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PMID: 37952131. PMID 37952131 | human trial |
| 2022 | Semaglutide | Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. PMID: 36216945. PMID 36216945 | human trial |
| 2022 | Semaglutide | Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes (STEP 8). JAMA. 2022;327(2):138-150. PMID: 35015037. PMID 35015037 | human trial |
| 2021 | Semaglutide | Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PMID: 33567185. PMID 33567185 | human trial |
| 2021 | Semaglutide | Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. PMID: 33667417. PMID 33667417 | human trial |
| 2021 | Semaglutide | Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021;325(14):1403-1413. PMID: 33625476. PMID 33625476 | human trial |
| 2021 | Semaglutide | Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021;325(14):1414-1425. PMID: 33755728. PMID 33755728 | human trial |
| 2021 | Semaglutide | Newsome PN, Buchholtz K, Cusi K, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021;384(12):1113-1124. PMID: 33185364. PMID 33185364 | human trial |
| 2019 | Semaglutide | Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019;42(9):1724-1732. PMID: 31186300. PMID 31186300 | human trial |
| 2016 | Semaglutide | Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN 6). N Engl J Med. 2016;375(19):1834-1844. PMID: 27633186. PMID 27633186 | human trial |
| 2019 | Semaglutide | Knudsen LB, Lau J. The Discovery and Development of Liraglutide and Semaglutide. Front Endocrinol. 2019;10:155. PMID: 31031702. PMID 31031702 | mechanism / discovery |
Related pair pages
More research context
Frequently asked
Have Eloralintide and Semaglutide been studied together?
Researchers have published mechanistic-level co-administration discussion of Eloralintide and Semaglutide. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Eloralintide and Semaglutide share?
Eloralintide and Semaglutide do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Eloralintide and Semaglutide?
Eloralintide: Investigational — Phase 3 enrollment initiated late 2025. Semaglutide: Approved (2017). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Eloralintide and Semaglutide?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Eloralintide profile and the Semaglutide profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026